Outlook Wealth Advisors LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Outlook Wealth Advisors LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,136 shares of the medical device company's stock, valued at approximately $477,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Thoroughbred Financial Services LLC bought a new stake in DexCom in the second quarter worth approximately $211,000. Envestnet Asset Management Inc. raised its stake in DexCom by 0.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 599,303 shares of the medical device company's stock valued at $67,949,000 after purchasing an additional 3,356 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after purchasing an additional 353,019 shares during the period. Dimensional Fund Advisors LP grew its position in DexCom by 41.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company's stock worth $104,282,000 after purchasing an additional 268,802 shares during the last quarter. Finally, Perennial Investment Advisors LLC increased its holdings in shares of DexCom by 7.4% during the 2nd quarter. Perennial Investment Advisors LLC now owns 3,156 shares of the medical device company's stock worth $358,000 after purchasing an additional 217 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 5.6 %

Shares of DXCM traded up $4.51 during mid-day trading on Thursday, hitting $84.91. 4,222,044 shares of the company's stock were exchanged, compared to its average volume of 3,636,278. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market cap of $33.17 billion, a PE ratio of 50.79, a P/E/G ratio of 2.00 and a beta of 1.12. The company has a 50-day simple moving average of $77.57 and a 200 day simple moving average of $78.37.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on DXCM shares. Citigroup increased their target price on shares of DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Leerink Partners cut their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Royal Bank of Canada decreased their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company increased their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group lifted their target price on shares of DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $99.29.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.